Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-Garcia M, Martinez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, Lopez-Botet M, Albanell J.

Clin Cancer Res. 2018 Dec 6. pii: clincanres.2365.2018. doi: 10.1158/1078-0432.CCR-18-2365. [Epub ahead of print]

PMID:
30523021
2.

Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.

Villarrubia N, Rodríguez-Martín E, Alari-Pahissa E, Aragón L, Castillo-Triviño T, Eixarch H, Ferrer JM, Martínez-Rodríguez JE, Massot M, Pinto-Medel MJ, Prada Á, Rodríguez-Acevedo B, Urbaneja P, Gascón-Gimenez F, Herrera G, Hernández-Clares R, Salgado MG, Oterino A, San Segundo D, Cuello JP, Gil-Herrera J, Cámara C, Gómez-Gutiérrez M, Martínez-Hernández E, Meca-Lallana V, Moga E, Muñoz-Calleja C, Querol L, Presas-Rodríguez S, Teniente-Serra A, Vlagea A, Muriel A, Roldán E, Villar LM.

Clin Chim Acta. 2019 Jan;488:135-142. doi: 10.1016/j.cca.2018.11.008. Epub 2018 Nov 5.

PMID:
30408481
3.

Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'?

Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE.

Eur J Neurol. 2018 Jul;25(7):925-933. doi: 10.1111/ene.13622. Epub 2018 Apr 15.

PMID:
29528545
4.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

5.

Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System.

Pupuleku A, Costa-García M, Farré D, Hengel H, Angulo A, Muntasell A, López-Botet M.

Front Immunol. 2017 Oct 24;8:1317. doi: 10.3389/fimmu.2017.01317. eCollection 2017.

6.

Impact of Zygosity on Bimodal Phenotype Distributions.

Holst-Hansen T, Abad E, Muntasell A, López-Botet M, Jensen MH, Trusina A, Garcia-Ojalvo J.

Biophys J. 2017 Jul 11;113(1):148-156. doi: 10.1016/j.bpj.2017.05.010.

7.

Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.

López-Montañés M, Alari-Pahissa E, Sintes J, Martínez-Rodríguez JE, Muntasell A, López-Botet M.

J Immunol. 2017 Jul 15;199(2):656-665. doi: 10.4049/jimmunol.1601574. Epub 2017 Jun 19.

8.

Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation.

López-Botet M, Vilches C, Redondo-Pachón D, Muntasell A, Pupuleku A, Yélamos J, Pascual J, Crespo M.

Front Immunol. 2017 Feb 16;8:166. doi: 10.3389/fimmu.2017.00166. eCollection 2017. Review.

9.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
10.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

11.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

12.

Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.

Redondo-Pachón D, Crespo M, Yélamos J, Muntasell A, Pérez-Sáez MJ, Pérez-Fernández S, Vila J, Vilches C, Pascual J, López-Botet M.

J Immunol. 2017 Jan 1;198(1):94-101. Epub 2016 Dec 2.

13.

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Oertel WH, Hallström Y, Saletu-Zyhlarz GM, Hopp M, Bosse B, Trenkwalder C; RELOXYN Study Group.

CNS Drugs. 2016 Aug;30(8):749-60. doi: 10.1007/s40263-016-0372-1.

14.

Development of the adaptive NK cell response to human cytomegalovirus in the context of aging.

López-Botet M, Muntasell A, Martínez-Rodríguez JE, López-Montañés M, Costa-García M, Pupuleku A.

Mech Ageing Dev. 2016 Sep;158:23-6. doi: 10.1016/j.mad.2016.06.010. Epub 2016 Jun 24. Review.

PMID:
27349430
15.

Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers.

Baía D, Pou J, Jones D, Mandelboim O, Trowsdale J, Muntasell A, López-Botet M.

Eur J Immunol. 2016 Jul;46(7):1681-90. doi: 10.1002/eji.201546149. Epub 2016 Jun 2.

16.

Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets.

Muntasell A, Pupuleku A, Cisneros E, Vera A, Moraru M, Vilches C, López-Botet M.

J Immunol. 2016 May 1;196(9):3818-27. doi: 10.4049/jimmunol.1502438. Epub 2016 Mar 18.

17.

Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.

Muntasell A, López-Botet M.

Clin Cancer Res. 2016 Apr 15;22(8):1831-3. doi: 10.1158/1078-0432.CCR-15-3168. Epub 2016 Feb 22.

18.

Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.

Muccio L, Bertaina A, Falco M, Pende D, Meazza R, Lopez-Botet M, Moretta L, Locatelli F, Moretta A, Della Chiesa M.

Haematologica. 2016 Mar;101(3):371-81. doi: 10.3324/haematol.2015.134155. Epub 2015 Dec 11.

19.

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct.

20.

Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.

Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M.

Mult Scler. 2016 May;22(6):741-52. doi: 10.1177/1352458515601215. Epub 2015 Sep 11.

PMID:
26362897

Supplemental Content

Loading ...
Support Center